Last reviewed · How we verify
NCT05528081: LMMM
Longitudinal Study of the Patients With Medication-overuse Headache or Migraine That Completed Baseline MRI
trial testing Phone interview in Migraine Disorders in 122 participants. Status unknown.
1 October 2024
Quick facts
| Lead sponsor | Wei Dai |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 122 |
| Start date | 1 October 2022 |
| Primary completion | 1 October 2024 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Phone interview
Conditions studied
- Migraine Disorders — all drugs for Migraine Disorders →
- Medication-overuse Headache — all drugs for Medication-overuse Headache →
Sponsor
Wei Dai
Who can join
Adults 18 to 65, any sex, with Migraine Disorders or Medication-overuse Headache. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phone interview research study for patients with migraine or medication-overuse headache (MOH) who have completed baseline MRI scans. Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans. The purpose of this study is to potentially identify the baseline brain functional or structural signatures (functional connectivity, regional homogeneity, amplitude of low frequency fluctuation, and so such) that are predictive of the short- and long- term outcomes as well as treatment response of migraine and MOH patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05528081
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Phone interview
Trials testing the same drug.
- NCT06279052 — Adolescent Projections During Transition in Prader-Willi Syndrome · NA · unknown
- NCT05271981 — Fertility After Uterine Artery Embolization · completed
- NCT04788433 — Registry of Coronavirus Complications - CORRELATION WITH GLYCOMIC PROFILE in COVID-19 Patients · completed
- NCT05808777 — Validation of the ICH Score for the Prediction of 12-month Functional Outcome in Patients With Primary Intracerebral Hem · completed
- NCT03447886 — Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Back · completed
Other recruiting trials for Migraine Disorders
Currently open trials in the same condition.
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT07093138 — Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatmen · Phase 4 · recruiting
- NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. · NA · recruiting
- NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation · NA · recruiting
- NCT06535880 — Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05528081 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wei Dai
- Last refreshed: 19 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05528081.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing